ContextVision Extraordinary General Meeting
On the 10th of December 2021, ContextVision AB held an Extraordinary General Meeting in Stockholm.
- The Board's proposal for a resolution on dividend of all shares in the Company’s wholly-owned subsidiary INIFY Laboratories AB containing the line of business Digital Pathology to the shareholders of ContextVision AB, was approved.
- No other matters were processed at the meeting.
Minutes of the meeting are attached hereto and will also be available on ContextVisions’ website www.contextvision.com
###
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
###
For further information, please contact:
Ann-Charlotte Linderoth (CFO)
tel +46 (0)8 7503550, e-mail ann-charlotte.linderoth@contextvision.se
###
About ContextVision
ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X- ray and MRI equipment around the world.
Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment.
ContextVision has built up a business unit for the fast-growing digital pathology market. We are re-investing significantly in our product portfolio of decision support tools, and we are dedicated to becoming a leading resource for pathologists to radically develop cancer diagnosis and improve patient care.
The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX.